End points for Phase II trials in intensive care: Recommendations from the Australian and New Zealand clinical trials group consensus panel meeting

Critical Care and Resuscitation

Volumn 14, Issue 3, 2012, Pages 211-215

  Young, Paul ^a,b   Hodgson, Carol ^c,d   Dulhunty, Joel ^e,f   Saxena, Manoj ^g,h   Bailey, Michael ^c   Bellomo, Rinaldo ^c,i   Davies, Andrew ^d   Finfer, Simon ^g,j,k   Kruger, Peter ^f,l   Lipman, Jeffrey ^e,f   Myburgh, John ^g,h   Peake, Sandra ^m   Seppelt, Ian ^g,n   Streat, Stephen ^o   Tate, Rhiannon ^p   Webb, Steven ^q  

^a WELLINGTON HOSPITAL   (New Zealand)

^b MEDICAL RESEARCH INSTITUTE OF NEW ZEALAND   (New Zealand)

^c MONASH UNIVERSITY   (Australia)

^d ALFRED HOSPITAL   (Australia)

^e ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^f UNIVERSITY OF QUEENSLAND   (Australia)

^g GEORGE INSTITUTE FOR GLOBAL HEALTH   (Australia)

^h UNIVERSITY OF NEW SOUTH WALES   (Australia)

ⁱ AUSTIN HOSPITAL   (Australia)

^j UNIVERSITY OF SYDNEY   (Australia)

^k ROYAL NORTH SHORE HOSPITAL   (Australia)

^l PRINCESS ALEXANDRA HOSPITAL   (Australia)

^m QUEEN ELIZABETH HOSPITAL   (Australia)

ⁿ NEPEAN HOSPITAL   (Australia)

^o AUCKLAND CITY HOSPITAL   (New Zealand)

^p Australian and New Zealand Intensive Care Society   (Australia)

^q ROYAL PERTH HOSPITAL   (Australia)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; AUSTRALIA; BIOASSAY; CRITICAL ILLNESS; HUMAN; MORTALITY; NEW ZEALAND; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL (TOPIC); SAMPLE SIZE;

AUSTRALIA; CLINICAL TRIALS, PHASE II AS TOPIC; CRITICAL ILLNESS; ENDPOINT DETERMINATION; HUMANS; NEW ZEALAND; OUTCOME ASSESSMENT (HEALTH CARE); SAMPLE SIZE;

EID: 84868244909     PISSN: 14412772     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Finfer S, Bellomo R, Boyce N, et al. A comparison of albumin and saline for fluid resuscitation in the intensive care unit. N Engl J Med 2004; 350: 2247-2256.
2. Finfer S, Chittock DR, Su S Y, et al. Intensive versus conventional glucose control in critically ill patients. N Engl J Med 2009; 360: 1283-1297.
3. Edwards P, Arango M, Balica L, et al. Final results of MRC CRASH, a randomised placebo-controlled trial of intravenous corticosteroid in adults with head injury-outcomes at 6 months. Lancet 2005; 365: 1957-1959.
4. Shakur H, Roberts I, Bautista R, et al. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial. Lancet 2010; 376: 23-32.
5. Aberegg SK, Richards DR, O'Brien JM. Delta inflation: a bias in the design of randomized controlled trials in critical care medicine. Crit Care 2010; 14: R77.
6. Ospina-Tascon GA, Buchele GL, Vincent JL. Multicenter, randomized, controlled trials evaluating mortality in intensive care: doomed to fail? Crit Care Med 2008; 36: 1311-1322.
7. Rubenfeld GD, Abraham E. When is a negative phase II trial truly negative? Am J Respir Crit Care Med 2008; 178: 554-555.
8. Spragg RG, Bernard GR, Checkley W, et al. Beyond mortality: future clinical research in acute lung injury. Am J Respir Crit Care Med 2010; 181: 1121-1127.
9. Reade MC, Angus DC. The clinical research enterprise in critical care: what's right, what's wrong, and what's ahead? Crit Care Med 2009; 37 (1 Suppl): S1-9.
10. Sevransky JE, Checkley W, Martin GS. Critical care trial design and interpretation: a primer. Critical care medicine 2010; 38: 1882-1889.
11. McAuley DF, O'Kane C, Griffiths MJ. A stepwise approach to justify phase III randomized clinical trials and enhance the likelihood of a positive result. Crit Care Med 2010; 38 (10 Suppl): S523-527.
12. Mokkink LB, Terwee CB, Knol DL, et al. The COSMIN checklist for evaluating the methodological quality of studies on measurement properties: a clarification of its content. BMC Med Res Methodol 2010; 10: 22.
13. Fine J, Gray JR. A proportional hazards model for the subdistribu-tion of a competing risk. J Am Stat Assoc 1999; 94: 496-509.
14. Schoenfeld DA, Bernard GR. Statistical evaluation of ventilator-free days as an efficacy measure in clinical trials of treatments for acute respiratory distress syndrome. Crit Care Med 2002; 30: 1772-1777.
15. Strom T, Martinussen T, Toft P. A protocol of no sedation for critically ill patients receiving mechanical ventilation: a randomised trial. Lancet 2010; 375: 475-480.
16. Ferrer M, Sellares J, Valencia M, et al. Non-invasive ventilation after extubation in hypercapnic patients with chronic respiratory disorders: randomised controlled trial. Lancet 2009; 374: 1082-1088.
17. Schweickert WD, Pohlman MC, Pohlman AS, et al. Early physical and occupational therapy in mechanically ventilated, critically ill patients: a randomised controlled trial. Lancet 2009; 373: 1874-1882.
18. Pandharipande P P, Pun BT, Herr DL, et al. Effect of sedation with dexmedetomidine vs lorazepam on acute brain dysfunction in mechanically ventilated patients: the MENDS randomized controlled trial. JAMA 2007; 298: 2644-2653.
19. Mercat A, Richard JC, Vielle B, et al. Positive end-expiratory pressure setting in adults with acute lung injury and acute respiratory distress syndrome: a randomized controlled trial. JAMA 2008; 299: 646-655.
20. Papazian L, Forel JM, Gacouin A, et al. Neuromuscular blockers in early acute respiratory distress syndrome. N Engl J Med 2010; 363: 1107-1116.
21. Wiedemann H P, Wheeler AP, Bernard GR, et al. Comparison of two fluid-management strategies in acute lung injury. N Engl J Med 2006; 354: 2564-2575.
22. Wheeler AP, Bernard GR, Thompson BT, et al. Pulmonary-artery versus central venous catheter to guide treatment of acute lung injury. N Engl J Med 2006; 354: 2213-2224.
23. Roquilly A, Mahe PJ, Seguin P, et al. Hydrocortisone therapy for patients with multiple trauma: the randomized controlled HYPOL-YTE study. JAMA 2011; 305: 1201-1209.
24. Barter PJ, Caulfield M, Eriksson M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007; 357: 2109-2122.
25. Calfee CS, Ware LB, Eisner MD, et al. Plasma receptor for advanced glycation end products and clinical outcomes in acute lung injury. Thorax 2008; 63: 1083-1089.
26. Ware LB, Matthay MA, Parsons PE, et al. Pathogenetic and prognostic significance of altered coagulation and fibrinolysis in acute lung injury/acute respiratory distress syndrome. Crit Care Med 2007; 35: 1821-1828.
27. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. Acute Respiratory Distress Syndrome Network. N Engl J Med 2000; 342: 1301-1308.